Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. (Q45368771)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Noel Jean Milpied

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Z Peric

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

P Chevallier

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

E Brissot

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

F Malard

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

T Guillaume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

J Delaunay

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

S Ayari

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

V Dubruille

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

S Le Gouill

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

B Mahe

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

T Gastinne

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

N Blin

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

B Saulquin

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

J-L Harousseau

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

P Moreau

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

M Coste-Burel

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

B-M Imbert-Marcille

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

M Mohty

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

25 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

932-938

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2011.26

23 January 2020

exact match

0 references

cites work

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Reduced-intensity conditioning transplantation in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

How I treat EBV lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Post-transplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Epstein-Barr virus (EBV)-DNA quantification in pediatric allogenic stem cell recipients: prediction of EBV-associated lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Cellular normalization of viral DNA loads on whole blood improves the clinical management of cytomegalovirus or Epstein Barr virus infections in the setting of pre-emptive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

Reduced-intensity conditioning for allogeneic stem cell transplantation: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

7 January 2021

Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

7 January 2021

Prompt versus preemptive intervention for EBV lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

7 January 2021

Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

7 January 2021

Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

7 January 2021

Regression modeling of competing risk using R: an in depth guide for clinicians

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

7 January 2021

Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

7 January 2021

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

7 January 2021

Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.26

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21350556%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

23 January 2020

1005543088

0 references

1 reference